USA-based Elevation Oncology, an innovative oncology company focused on the discovery and development of selective cancer ...

Investing.com -- Lonza’s shares rose over 6% on Thursday following the company’s announcement of plans to divest its Capsules ...

By Isabel Demetz (Reuters) -Swiss contract drugmaker Lonza plans to simplify its structure and exit its capsules and health ...

Elevation Oncology has tapped Lonza’s Synaffix to support the expansion of its pipeline, agreeing to pay up to $368 million ...

With a new CEO at the helm, Swiss CDMO Lonza is looking to revivify its business by doubling down on contract manufacturing ...

Recent developments in the health sector include a dosing pause in Keros Therapeutics' drug trial, Corcept Therapeutics' ALS ...

Synaffix B.V., a Lonza company (SIX: LONN) focused on commercializing its clinical-stage platform technology for the development ...

Licensing agreement gives Elevation Oncology access to Synaffix's ADC technology for one program in combination with SYNstatin EElevation Oncology nominates a novel HER3 ADC candidate EO-1022 ...

Swiss healthcare manufacturing organization Lonza saw its shares rise 7% to 559.40 francs in early trading, as it announced ...

The life-sciences company will focus on its core business, including drug development, with restructuring and a divestment ...

European stocks edged higher on Thursday, as investors braced for a rate cut from the European Central Bank and awaited hints ...

Lonza Group AG / Key word (s): Strategic Company Decision Lonza Investor Update 2024 Outlines Strategy, New Organizational Structure and Guidance 12-Dec-2024 / 06:25 CET/CEST Release of an ad hoc ...